Open Access. Powered by Scholars. Published by Universities.®
Zucker School of Medicine at Hofstra/Northwell
PERIPROCEDURAL ANTICOAGULATION;; RADIOFREQUENCY ABLATION;; ANTITHROMBOTIC;; THERAPY;; PREVENT STROKE;; WARFARIN;; DABIGATRAN;; SAFETY;; RIVAROXABAN;; INSIGHTS;; REVERSAL;; Cardiac & Cardiovascular Systems
Articles 1 - 1 of 1
Full-Text Articles in Cardiology
Outcomes Registry For Better Informed Treatment Of Atrial Fibrillation Ii: Rationale And Design Of The Orbit-Af Ii Registry, B. A. Steinberg, R. G. Blanco, D. Ollis, S. Kim, D. N. Holmes, P. R. Kowey, G. C. Fonarow, J. Ansell, B. Gersh, J. P. Piccini, +6 Additional Authors
Outcomes Registry For Better Informed Treatment Of Atrial Fibrillation Ii: Rationale And Design Of The Orbit-Af Ii Registry, B. A. Steinberg, R. G. Blanco, D. Ollis, S. Kim, D. N. Holmes, P. R. Kowey, G. C. Fonarow, J. Ansell, B. Gersh, J. P. Piccini, +6 Additional Authors
Journal Articles
Background Recent clinical trials have demonstrated the safety and efficacy of several non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF). However, there are limited data on their use and outcomes in routine clinical practice, particularly among patients newly diagnosed as having AF and patients with AF recently transitioned to a NOAC. Methods/Design ORBIT-AF II is a multicenter, national registry of patients with AF that is enrolling up to 15,000 newly diagnosed patients with AF and/or those with AF recently transitioned to a NOAC from 300 US outpatient practices. These patients will be followed for up to …